Appendiceal neuroendocrine neoplasms (NENs) are rare and usually incidentally discovered. Most cases are clinically indolent, although the rare aggressive ones are poorly predictable. The aim of this study was to test the applicability and prognostic significance of the new World Health Organization (WHO) classification and to test the several pathologic features and TNM staging systems (American Joint Committee on Cancer and European Neuroendocrine Tumor Society) in these tumors. A multi-institutional retrospective series of 138 appendiceal NENs was selected on the basis of the availability of both pathologic material and clinical information, including follow-up data. All cases were reviewed to record pathologic features and to apply year 2000 and 2010 WHO classifications, as well as European Neuroendocrine Tumor Society and American Joint Committee on Cancer TNM stages. Clinical and pathologic characteristics were compared with disease outcome by contingency, univariate, and multivariate survival analyses. Although up to one third of cases presented several malignancyassociated pathologic features, only 4 patients died of the disease. Adverse outcome was significantly associated with extramural extension (including mesoappendix), well-differentiated carcinoma diagnosis (2000 WHO classification), pT3-4 stage, older age, and presence of positive resection margins, but not with tumor size, mitotic or proliferative indexes, and, con-sequently, 2010 WHO grading. In the appendix, at variance with midgut/hindgut NENs, the 2000 WHO classification performs better than the grading-based 2010 WHO scheme and, together with tumor stage, is the most relevant parameter associated with clinical aggressiveness.
N euroendocrine neoplasms (NENs) of the appendix are rare and in general incidentally found in the tip or body of the appendix after appendectomy for inflammatory processes. Data from Surveillance, Epidemiology and End Results (SEER) databases in the United States set their incidence in the general population at 0.1 to 0.2/100,000 per year, a figure stable along the last 30 years, with a slight female predominance and a mean age of 48 years. 1, 2 Similarly, recent data from European registries reported an incidence of 0.08/100,000 with a median age of 38 years. 3 In surgical case series, the occurrence of NENs is encountered in <0.5% of all appendectomies, although this tumor type represents the most frequent neoplasm in this location [4] [5] [6] [7] [8] [9] and the second most frequent NEN within the gastrointestinal tract. 3, 10 The prognosis is generally good with a reported 5-year survival varying from 88% to 94% in patients with localized disease, 78% to 84% in patients with regional dissemination, and 25% to 26% in patients with distant metastases. 1, 2, 11 However, survival data from SEER databases probably overestimate the clinical aggressiveness of appendiceal NENs because of their malignancy-based selection criteria. In contrast, the rare cases that follow an aggressive course with local recurrence and/or distant metastases are poorly predictable at time of diagnosis. Tumor size is generally considered a major predictor of prognosis, as cases <1 cm almost invariably have favorable outcome, whereas those with a diameter exceeding 2 cm are associated with a 5-year mortality of 29%. 11 More controversial prognostic factors include lymphovascular invasion, subserosal invasion, extension to the mesoappendix, and infiltration of the appendiceal base. Even the presence of lymph node metastases does not seem to be associated with a different 10-year survival rate, irrespective of the tumor size. 12 On the search for the most appropriate pathologic characterization and prognostication of appendiceal NENs, minimal requirements for pathologic reporting in these tumors have been proposed, but the real impact of all such information is far from being established. 11, 13 The evaluation of mitotic and proliferative indexes has been recommended 11, 13, 14 and, as a matter of fact, is now part of the World Health Organization (WHO) classification scheme of gastrointestinal NENs, 15 but their clinical usefulness in appendiceal NENs has not been tested yet. Moreover, 2 different staging systems exist, 1 proposed by the European Neuroendocrine Tumor Society (ENETS) in 2007 16 and the other recently proposed by the American Joint Committee on Cancer (AJCC) 17 and incorporated in the 2010 WHO classification. 15 Although in both classifications the "T" category is defined by tumor size and depth of invasion, the 2 systems differ considerably in the cutoff values and classification rules with a major shift between "organ confined" and "locally advanced" stages in a relevant number of case.
As a consequence, the best therapeutic strategy for these tumors is not well established. In fact, in pediatric populations the rate of patients cured by appendectomy is approaching 100%, 18, 19 thus questioning, according to some authors, the real need of routinely examining the appendiceal specimens. 20 Conversely, the recent consensus guidelines from ENETS 21 and North American Neuroendocrine Tumor Society 11 claimed the need for right hemicolectomy in a relevant proportion of cases (ie, those with a tumor size >2 cm, accounting for up to 17% of all cases).
On the basis of the foregoing, a retrospective study was designed with the aim of testing the applicability and prognostic significance of the previous 22 and current 15 WHO classification schemes, of different pathologic parameters and TNM staging systems (2010 WHO/AJCC and ENETS 2007), to determine the most clinically relevant parameters for the pathologic characterization of appendiceal NENs.
MATERIALS AND METHODS

Case Selection
A database search including topography "appendix" and Systematized Nomenclature of Medicine (SNOMED) diagnoses "carcinoid" and "neuroendocrine carcinoma" was performed in 7 pathology units of a North-Western Italian Province in Piedmont. For all cases the availability of representative histologic material was a major criterion for entering the study. A diagnosis of primary appendiceal NEN was done in 168 unselected cases from the year 1988 to 2009. Case distribution was as follows: 45 cases from the Molinette Hospital, Turin; 25 cases from the Alba Hospital; 25 cases from the Santa Croce Hospital, Moncalieri; 24 cases from the Giovanni Bosco Hospital, Turin; 19 cases from the Santa Croce and Carle Hospital, Cuneo; 15 cases from the San Luigi Hospital, Orbassano; 15 cases from the Mauriziano Hospital, Turin. In all but 21 cases, detailed clinical and pathologic information including follow-up data were obtained from pathologic reports, clinical charts, and/or register offices.
Pathologic Revision and Immunohistochemistry
A total of 147 cases were entered in the study and were reviewed by the local pathologists and then reclassified centrally by 2 authors (L.D., M.V.) according to the 2000 and 2010 WHO classification schemes. 15, 22 The neuroendocrine phenotype was assessed at the time of original diagnosis or upon revision by means of immunostaining with chromogranin A (clone LK2H10, diluted 1:800; Neo-Markers, Fremont, CA) and/or synaptophysin (clone Sy38, diluted 1:100; DakoCytomation, Glostrup, Denmark). The mitotic index was expressed as the number of mitoses per 10 HPF (approximately 2 mm 2 ) evaluating at least 50 HPF (or the entire tumor area in the case of small tumors). Ki-67 proliferative index was assessed in all but 19 cases (clone MIB-1, diluted 1:150; Dako) following 2010 WHO recommendations. 15 The following pathologic parameters were recorded following recently proposed protocols and checklists 13 : size of the lesion, location within the appendix, percentage of appendix wall involvement, depth of invasion, extent of subserosal invasion, presence of mesoappendix invasion, presence of vascular and perineural invasion, status of the resection margin, growth pattern, and pathologic T stage, according to both ENETS 16 and 2010 WHO/AJCC 15,17 staging systems.
Statistical Analysis
Dichotomic clinical and pathologic variables were compared with 2000 and 2010 WHO classifications and disease status using w 2 and Fisher exact tests, whereas continuous variables were compared using the t or analysis of variance tests. The Spearman correlation was used to correlate the tumor grade evaluated as mitotic or proliferative indexes. Disease-related survival curves were computed using the Kaplan-Meier method and compared using the log rank test in univariate analysis. All parameters with a borderline or significant impact on survival at univariate analysis were considered for multivariate analysis using the Cox proportional hazard model. Statistical significance was set at P < 0.05. All tests were performed using GraphPad version 5.0 and STATIS-TICA version 7.0 softwares.
RESULTS
Classification and Clinical Data
Nine cases with goblet cell carcinoid features were reclassified as mixed adenoneuroendocrine carcinomas and were excluded from further analysis on the basis of the new 2010 WHO classification.
Of the 138 remaining cases, 59 were classified as well-differentiated endocrine tumors, benign, 34 as welldifferentiated endocrine tumors, uncertain behavior, and 45 as well-differentiated endocrine carcinomas according to the 2000 WHO nomenclature. Moreover, on the basis of the new 2010 WHO classification, 120 cases were graded as neuroendocrine tumor G1 and 18 cases as neuroendocrine tumor G2. A comparison of case distribution within the 2 classification schemes is illustrated in Figure 1 . No case was diagnosed as poorly differentiated/neuroendocrine carcinoma G3.
In 17 cases, a predominant tubular growth was observed with occasionally associated Paneth-like cells ( Fig. 2A) , whereas in all other cases the growth pattern was typically organoid, with tumor cells arranged in islets or ribbons growing in a variably desmoplastic stroma ( Fig. 2B) , irrespective of the depth of invasion (Fig. 2C) .
A total of 61 male and 77 female patients of a mean age of 38 years (range, 8 to 86 y; median 34 y) were included. Appendectomy was the primary intervention in all but 15 patients who directly underwent hemicolectomy (10 cases), or appendectomy concurrent to hysterectomy with oophorectomy (4 cases) or cystectomy (1 case) for other diseases. Right hemicolectomy followed appendectomy in another 4 patients, all having an original diagnosis of welldifferentiated endocrine carcinoma according to the 2000 WHO classification. In 4 patients, information on surgical procedures possibly performed after appendectomy was not available. Specific nodal status was assessed in the 14 patients treated with hemicolectomy, and all were staged pN0. Concurrent or subsequent associated neoplastic diseases included adenocarcinoma originated from the colon (10 cases), endometrium (2 cases), biliary tract (2 cases) and stomach (1 case), squamous cell carcinomas from the lung and uterine cervix (1 case each), bladder urothelial carcinoma (1 case), and serous papillary ovarian carcinoma (1 case). Mean follow-up time was 86.5 months (range, 1 to 267 mo). Overall, 24 patients had died, but only 4 patients died of their appendiceal tumor. Specific surgical procedures for these cases were appendectomy only in 2 cases, primary hemicolectomy in 1 case, appendectomy and subsequent hemicolectomy in the latter case. Owing to the incompleteness of clinical information regarding tumor relapse and disease status in two thirds of the patients alive at last follow-up, disease-free and time to progression survival analyses could not be performed.
Clinicopathologic Correlations and Survival Analysis
Clinical and pathologic parameters were compared with the 2 different WHO classification systems (Table 1) . Tumor groups defined according to the 2000 WHO classification were different in terms of tumor size, extent of appendiceal wall involved, presence of positive resection margins, mean proliferation index, and tumor grade. The 2 groups neuroendocrine tumor G1 and neuroendocrine tumor G2, as defined by the 2010 WHO classification, differed in terms of age, tumor size, percentage of appendiceal wall involved, depth of invasion, presence of mesoappendix infiltration, and presence of vascular and perineural invasion.
Disease-related survival analysis was mostly limited by the small number of patients who died of the disease (responsible for the extremely wide 95% confidential intervals), although this limitation emphasizes that fatal outcome is a very rare event in appendiceal NENs, even in advanced stages. Univariate survival analysis ( Table 2) showed that the invasion of or beyond the subserosa and of the mesoappendix impacted on survival, whereas tumor size per se did not, either grouped according to the mean value or using 1 cm as the cutoff. Patients having a tumor size >2 cm were all alive at the time of follow-up. Moreover, the presence of positive resection margins and age above the median value were associated with a shorter survival. A trend to significance was also observed for female sex and presence of vascular invasion. By contrast, neither mitotic count nor proliferation index were associated with the risk of disease-specific death. As a subanalysis of these latter parameters, we separately compared the 2010 WHO tumor grade as defined by mitotic count or Ki-67 index (the distribution of these parameters is illustrated in Fig. 3) ; although significantly correlated (P < 0.0001), the Spearman r coefficient was only moderate (0.394) because of 18 discordant cases.
When comparing WHO classification schemes at contingency and univariate survival analyses, only the 2000 WHO classification was associated with prognosis in our series ( Table 3 ) ( Fig. 4, left) . However, the most significant prognostic indicator was represented by the pT stage, according to both ENETS and 2010 WHO/AJCC systems ( Fig. 4, right) . Owing to the very small number of patients who died of the disease, the value of median survival was 
DISCUSSION
To our knowledge, this is the first study specifically designed on appendiceal neuroendocrine tumors to test the applicability of the novel WHO and TNM classifications of gastrointestinal NENs and to compare detailed pathologic features with clinical outcome. Herein, we present the evidence that, despite a relatively high frequency of malignancy-related parameters, appendiceal neuroendocrine tumors are almost invariably indolent and that pT stage but not the new 2010 WHO grading system seems to be the best predictor of adverse outcome in the small proportion of clinically aggressive cases investigated in this study.
The summary of clinical and pathologic findings of the whole series is in line with the available literature. The slight female predominance and the mean age <40 years were comparable with other series, 2,3 as were the distribution of size and depth of invasion. 7, 12 No case of neuroendocrine carcinoma G3 was detected in our series, confirming the extreme rarity of poorly differentiated cases in this location, at variance with NENs developing in the right colon.
The study was designed first to verify the practical applicability of a wide set of parameters in the pathologic characterization of appendiceal NENs, following recent recommendations, 11, 13, 14 and then to test their distribution in a large retrospective case series classified according to both 2000 and 2010 WHO classifications, as compared with clinical outcome. All these features are variably included in (old) classification or staging schemes or considered of clinical value, although their distribution is poorly detailed in the literature, which is mostly based on cancer registry series without pathologic (re)evaluation. The unselected nature of the present series (with the exclusion of cases lacking pathologic material available for review) allowed us to define the impact of their recognition and association with disease outcome more closely to the real diagnostic practice. By univariate survival analysis, extramural invasion, invasion of the mesoappendix, and presence of positive resection margins were statistically associated with shorter disease-related survival. As expected, a strong impact on survival was observed also for 2000 WHO classification, which is basically based on the above parameters. By contrast, neither Ki-67/ mitotic indexes per se nor 2010 WHO grading-based classification was associated with a specific survival. In fact, 3 of 4 patients who died of the disease had G1 tumors. It is worth noticing that the mean mitotic and proliferation indexes in the whole series were quite low (0.7 and 1.9, respectively), and only 13% of cases were G2, as compared with recent data on midgut and hindgut NENs, detecting up to 32% of G2 tumors. 23 Apart from biological considerations on the low proliferative properties of appendiceal NENs, this observation suggests that cutoff levels proposed for grading are inadequate for this particular location, as also supported by the poor correlation of individual mitotic and Ki-67 indexes in the present series, as opposed to other gastrointestinal locations. 24 The pathologic T stage according to both ENETS and AJCC was the most significant feature associated with a shorter survival; this finding is of special relevance, as the 2 schemes are quite different and are based on divergent rules for classification, generally the former being more invasion oriented and the latter more size oriented. However, the ENETS pT stage seemed to be less specific; in fact, although all patients who died of the disease were staged pT3 or 4, high tumor stage (including 7 pT4 cases) was also observed in up to 25% of patients alive at the time of follow-up. Moreover, although limited by the small number of patients who died of the disease, the prognostic strength of 2010 WHO/AJCC pT stage was confirmed by multivariate analysis, as compared with the status of the resection margins and size. It should be outlined, however, that stage-specific analysis in this paper was limited to "T" stage because of the absence of cases with positive lymph nodes (among those that underwent node dissection). In addition, age above the median was also slightly associated with a shorter diseaserelated survival, a finding previously not specifically reported in the literature. Finally, we could not confirm the major prognostic significance of size, as proposed in the literature, as none of the 4 patients who died of their disease had a tumor size Z2 cm.
The clinical meaning of the present findings is difficult to assess, but in general it can be suggested that the diagnostic procedures, according to the currently proposed pathologic datasets for the appendiceal location, may overestimate the real clinical aggressiveness of the lesion. It is stated in both European 21 and American 11 guidelines that a size >2 cm, positive resection margins, deep invasion of the mesoappendix, presence of lymphovascular invasion, and intermediate grade (G2) are all features supporting right hemicolectomy. A recent retrospective study supports this recommendation, as 4 of 12 patients who underwent hemicolectomy for tumors >2 cm or with Ki-67 > 2% and/or extended to the mesoappendix or appendiceal base had residual disease or nodal metastases. 25 However, our data claim that at least some of the above (namely size, vascular invasion, and tumor grade) might be reconsidered in future guidelines to refine criteria for right hemicolectomy and prevent overtreatment in these patients.
In conclusion, this retrospective study describes a spectrum of appendiceal NENs having a low grade, a variable stage, but an indolent course in the vast majority of cases. In this specific location, mesoappendix invasion (and the 2000 WHO classification), positive resection margins, and tumor stage were the most relevant features associated with clinical aggressiveness, whereas, at variance with midgut/hindgut tumors, the 2010 WHO grading system did not perform so well. With regard to the tumor stage, it seemed that the ENETS system produced an overestimation, whereas the 2010 WHO/AJCC TNM system was more accurate and specific in selecting the very few aggressive and fatal cases.
